Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Breast cancer treatment efficacy can be compromised by drug resistance.
• Histone deacetylase inhibitors are emerging as potential therapeutic agents.
• Valproic acid (VPA) is a clinically available histone deacetylase inhibitor.

Purpose of the Study:

• To investigate the anti-tumor effects of valproic acid (VPA) on estrogen-sensitive and -insensitive breast cancer cells.
• To determine VPA's impact on cell viability, cell cycle, and apoptosis in breast cancer models.
• To assess the potential of VPA as a novel therapeutic strategy for breast cancer.

Main Methods:

• Treatment of estrogen-sensitive (MCF-7, ZR-75-1) and potentially estrogen-insensitive breast cancer cells with VPA at a clinically relevant concentration.
• Assessment of cell viability, cell cycle progression, and apoptosis induction.
• Analysis of key protein expression related to cell cycle (p21) and apoptosis (Bcl-2, Bak).

Main Results:

• VPA significantly reduced cell viability in estrogen-sensitive breast cancer cell lines.
• VPA induced p21 expression and impaired cell cycle progression.
• MCF-7 cells exhibited massive sub-G1 accumulation and apoptosis, with down-regulation of Bcl-2 and up-regulation of Bak.
• ZR-75-1 cells showed selective G1 arrest.

Conclusions:

• Valproic acid demonstrates potent antiproliferative and pro-apoptotic effects in estrogen-sensitive breast cancer cells.
• VPA's ability to overcome resistance mechanisms warrants further investigation.
• VPA represents a promising therapeutic agent for breast cancer treatment, particularly in estrogen-sensitive subtypes.